Goldman Sachs Initiates Coverage of Genomic Health with Neutral Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Goldman Sachs today initiated coverage of Genomic Health with a Neutral rating and a six-month price target on its stock of $36.

In a research note, analyst Isaac Ro noted the growth potential of the Redwood City, Calif.-based firm's new products, but said that costs associated with those products will offset growth. Additionally, the company faces increased competition as well as a murky regulatory environment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.